Menu Search
Equities

Alnylam Pharmaceuticals Inc

ALNY:NSQ

Alnylam Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)249.60
  • Today's Change0.805 / 0.32%
  • Shares traded191.20k
  • 1 Year change+52.49%
  • Beta0.3262
Data delayed at least 15 minutes, as of Nov 21 2024 17:24 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy7
Outperform17
Hold7
Sell0
Strong Sell1

Share price forecast in USD

The 27 analysts offering 12 month price targets for Alnylam Pharmaceuticals, Inc. have a median target of 300.00, with a high estimate of 400.00 and a low estimate of 178.00. The median estimate represents a 20.58% increase from the last price of 248.79.
High60.8%400.00
Med20.6%300.00
Low-28.5%178.00

Earnings history & estimates in USD

On Oct 31, 2024, Alnylam Pharmaceuticals, Inc. reported 3rd quarter 2024 losses of -0.87 per share. This result was in line with the consensus of the 22 analysts following the company and under-performed last year's 3rd quarter results by -2.02.
The next earnings announcement is expected on Feb 13, 2025.
Average growth rate-147.17%
Alnylam Pharmaceuticals, Inc. reported annual 2023 losses of -3.52 per share on Feb 15, 2024.
Average growth rate+11.12%
More ▼

Revenue history & estimates in USD

Alnylam Pharmaceuticals, Inc. had 3rd quarter 2024 revenues of 500.92m. This missed the 533.10m consensus estimate of the 23 analysts following the company. This was 56.89% above the prior year's 3rd quarter results.
Average growth rate-4.90%
Alnylam Pharmaceuticals, Inc. had revenues for the full year 2023 of 1.83bn. This was 76.23% above the prior year's results.
Average growth rate+73.67%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.